DailyIQ
Last updatedUpdating…

OSCR·Oscar Health, Inc.

$34.34
+0.55 (+1.63%)
After Hours
High
$34.53
Open
$33.67
Market Cap
10.19B
52W High
$36.25
Low
$33.21
P. Close
$34.34
P/E
18.50
52W Low
$10.68
Fwd P/E
15.21
DailyIQ Est.
$36.96
Inst. Ownership
30.7%
Short Interest
5.45%
Days to Cover
2.7
Technical Score (1D)
86
BULLISH
News Sentiment
73
BULLISH
On Oct 14, analysts raised Oscar Health’s earnings estimates and highlighted improved utilization trends, positioning the company as potentially 94 % undervalued relative to a fair‑value target of $583.34. On Oct 13, Oscar Health reported record profitability, rising revenue, and growing membership, prompting analysts to reassess the company’s valuation and suggesting a potential upside if the market revises expectations for future profitability. On Oct 13, the company also raised its 2026 operating earnings outlook to $500‑$700 million from $250‑$450 million after a strong second‑quarter performance, while maintaining its 2026 revenue forecast at $18.7‑$19 billion. On Oct 13, Oscar Health posted a 70.4 % year‑over‑year revenue increase to $4.9 billion in Q2 2026, driven by a 46.2 % rise in membership to 2.96 million, and noted that the stock trades at a sizable premium, raising valuation concerns. On Oct 13, the company’s shares were reported to have increased, driven by a 46.2 % rise in members to 2.96 million during Q2 2026, and the medical loss ratio improved from 83 % to 75 %, with management projecting a full‑year ratio of 81‑82 %. These developments were reported as reinforcing the bullish case for Oscar Health and supporting a positive outlook, with analysts noting the company’s competitive positioning amid a contracting ACA market.
LOW TARGET
$27 -21.3%
2 analysts
MEAN TARGET
$36 +6.1%
12 analysts
HIGH TARGET
$49 +42.8%
6 analysts
PRICE RANGE
$27.00 - $49.00
SB / B / H / S / SS
2/7/9/1/1
DAILYIQ EST.
$36.96 (+7.7%)
Sector
Healthcare
Industry
Healthcare Plans
Exchange
NYQ
Country
United States
Symbol
OSCR
Description
Oscar Health, Inc. is a healthcare technology firm providing health plans to individuals, families, and employer groups within the United States. The company distinguishes itself through its integrated approach, offering not only insurance plans but also the +Oscar platform, which supports other healthcare entities. This platform provides services like Campaign Builder, a tool designed to enhance engagement and recommendations for healthcare providers and payers. Oscar Health's business model also includes reinsurance offerings. Formerly known as Mulberry Health Inc., the company adopted its current name in January 2021 and was established in 2012, with its headquarters located in New York, New York.
Bought (1Y)
0 shares
$0
Sold (1Y)
4,694,315 shares
$136.1M
Gassen William-
Award/Grant698 shares2026-10-08
Sankaran Sid-
Award/Grant1,472 shares2026-10-08
Plouffe David-
Award/Grant641 shares2026-10-08
WITTMAN VANESSA AMES-
Sell25,000 shares2026-09-18
Thrive Partners II GP, LLC-
J75,520 shares2026-09-18
55/ 100
Neutral / mixed
Overall: Neutral
✓Revenue growing year over year
✕Negative net margin
✓Positive operating cash flow
Net Margin
-1549.9%
Revenue CAGR
-37.7%
Current Ratio
0.95x
Debt / Equity
0.44x
Return on Equity
-45.3%
Earnings Summary
Oscar Health, Inc. is a healthcare technology firm that offers health plans to individuals, families, and employer groups while also providing the +Oscar platform to other healthcare entities; it operates within the healthcare plans industry. In the latest two quarters, revenue fell from $4.6472 billion in Q1 2026 to $4.8802 billion in Q2 2026, a 5.4% increase, while EPS rose from $2.07 to $1.10, a 47.6% decline, reflecting a sharp margin contraction; the company beat estimates in Q1 2026 (actual $2.07 vs. $1.1 estimate) but missed in Q2 2026 (actual $1.10 vs. $0.3935 estimate). Historically, Oscar has shown volatile earnings, with a 70.4% revenue jump in Q2 2026 driven by membership growth, yet experienced a significant decline in operating earnings in Q4 2025 when revenue fell to $2.8052 billion; the firm has alternated between profitable and loss‑making quarters, with EPS swings from negative to positive territory. Recent news reports that Oscar raised its 2026 operating earnings outlook to $500–$700 million after a strong Q2 2026 performance, citing improved underwriting, expense efficiency, and AI‑driven cost control; analysts also noted a 46.2% membership increase and a medical loss ratio improvement to 75%, underscoring the company’s focus on margin expansion.

EPS

EstBeatMiss
$-1.74$-0.66$0.41$1.49$2.57Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$-0.17 - -
Q2'26$0.39$1.10+179.5%
Q1'26$1.10$2.07+88.2%
Q4'25$1.04$-1.24-218.9%
Q3'25$-0.58$-0.53+8.7%
Q2'25$-0.84$-0.89-6.5%

Revenue

EstBeatMiss
$2.5B$3.2B$3.9B$4.5B$5.2BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$4.8B - -
Q2'26$4.8B$4.9B+0.7%
Q1'26$4.9B$4.6B-5.5%
Q4'25$4.3B$2.8B-34.5%
Q3'25 - $3.0B -
Q2'25 - $2.9B -

Market Data

OSCR Stock Snapshot

BULLISH86/100
$34.00−$0.34 (1.0%)
Market cap
10.19B
P/E ratio
18.5
Day range
$33.21 – $34.53
News sentiment
73/100 · Bullish
Analyst target
$36.40 (+7.1%)
Consensus
Hold · 20 analysts
52-week range+218.4% off low · -6.2% from high
$10.68$36.25
Price $34.00 DailyIQ Est. $36.96

The signal on OSCR is bullish: price action is confirming the underlying trend, not fighting it. Institutional coverage is thorough here, so shifts in analyst expectations show up in price quickly.

Reverse DCF

What growth is priced into OSCR?

CHEAP

At today's price, Oscar Health, Inc. needs to grow free cash flow about -9.9% a year for the next 10 years to justify its valuation at a 10.82% cost of capital. Over its actual history it has compounded free cash flow at 41.9% a year, so the market is asking for 51.8 percentage points below its own delivered rate. On that basis OSCR looks priced below what its own growth record supports.

Implied FCF growth
-9.9%
Historical FCF CAGR
41.9%
Growth gap
-51.8 pts
Verdict
CHEAP
Discount rate (WACC)
10.82%
Beta
1.18

Behaviour On Record

What OSCR's own history says about today's numbers

Realized volatility (21d)
42.4% 4th pct
Below its peak
-8.7%
vs 200-day average
+50.7%
Up days (1y)
47%

Oscar Health, Inc. is currently running 42.4% annualised volatility over the last 21 sessions. Measured against OSCR's own 5 years of daily returns rather than a market-wide average, that is the 4th percentile — unusually subdued by its own history, against a typical reading of 69.4%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

OSCR is trading -8.7% below its running peak. Across 5 full years on file, its median worst-drawdown-in-a-year was -49.3%, and the deepest was -79.4% in 2021. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +50.7% from its 200-day moving average. Against every other day in its history, that gap ranks at the 80th percentile — a wider gap than this stock usually carries. Over the past year OSCR closed higher on 47% of sessions, and it is currently 1 session into a falling streak.

On October specifically: over 5 years of records, OSCR finished the month higher 1 of 5 times, with a median return of -8.1% and an average of -11.3%. Its strongest month historically has been January at +18.7% on average, its weakest October at -11.3%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: OSCR has opened more than 2% away from the prior close in 285 of 1,392 sessions (20.5% of the time), with the largest gaps running +19.0% and -7.9%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, OSCR moved an average of 5.3% in the session after earnings, closing higher 3 of those 3 times, with a median move of +5.2% and a largest of +5.8%.

All figures computed from 1,394 daily closes between 2021-03-03 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against OSCR's own 6-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of OSCR's sector?

Oscar Health, Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Insurance industry group, OSCR ranks 8th of 15 tracked industries, improving.

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
82
Industry rank
#8 of 15

Options Market

What is the options market pricing for OSCR?

CallsPuts

For Oscar Health, Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.38), with at-the-money implied volatility around 70.5%. The options market is pricing roughly a ±4.8% move by that expiry — a range of about $31.65–$34.81.

Put/call ratio (2026-10-16)
0.38
ATM implied volatility
70.5%
Total open interest
32,802
Expected move by 2026-10-16
±4.8% ($31.65–$34.81)

Analyst Rating Changes

Are analysts turning bullish or bearish on OSCR?

UBS most recently reiterated its rating on Oscar Health, Inc. to Neutral on Oct 12, 2026 with a price target of $36 (from $26). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
UBS — Neutral
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 12, 2026UBSMaintainedNeutral$26 → $36
Sep 18, 2026Raymond JamesMaintainedOutperform$34 → $42
Sep 17, 2026B of A SecuritiesMaintainedUnderperform$28 → $30
Sep 17, 2026Stephens & Co.ReiteratedEqual-Weight$34
Sep 17, 2026BarclaysMaintainedOverweight$39 → $49
Sep 17, 2026BairdMaintainedNeutral$27 → $33
Aug 13, 2026Wells FargoMaintainedEqual-Weight$20 → $27
Aug 7, 2026UBSMaintainedNeutral$20 → $26
Aug 7, 2026BarclaysMaintainedOverweight$35 → $39
Jun 10, 2026BarclaysUpgradeEqual-Weight → Overweight$30 → $35
May 26, 2026BarclaysMaintainedEqual-Weight$21 → $30
May 7, 2026UBSMaintainedNeutral$15 → $20

Peers & ETF holders

OSCR peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

73/100
Strong NegativeNeutralStrong Positive
BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Oscar Health’s analysts raised earnings estimates and highlighted improved utilization trends, positioning the company as potentially 94% undervalued relative to a fair‑value target of $583.34. The narrative emphasized the stock’s strong year‑to‑date performance and suggested a significant upside if the market incorporates the new guidance. The article framed the valuation gap as a catalyst for a potential rally ahead of the upcoming quarterly report.
What did this article say?
Oscar Health reported record profitability, rising revenue, and growing membership, prompting analysts to reassess the company’s valuation. The article highlighted that the current share price may not fully reflect the earnings power generated, suggesting a potential upside if investors adjust expectations for future profitability. The focus was on whether the stock’s recent gains align with the underlying financial performance and the implications for the next few years.
What did this article say?
Oscar Health, Inc. (OSCR) raised its 2026 operating earnings outlook to $500‑$700 million from $250‑$450 million after a strong second‑quarter performance. The company maintained its 2026 revenue forecast at $18.7‑$19 billion, indicating that the upside is driven primarily by margin improvements rather than top‑line growth. Improved underwriting, expense efficiency, and technology leverage contributed to a $415.3 million adjusted EBITDA, up from a $199.4 million loss a year earlier. The guidance shift signals confidence in sustained profitability, though higher churn and seasonal costs are noted for the second half.
What did this article say?
Oscar Health (OSCR) reported a 70.4% year‑over‑year revenue increase to $4.9 billion in Q2 2026, driven by a 46.2% rise in membership to 2.96 million. The company’s ACA individual‑market expansion and new ICHRA, CHOICE, and Lucie offerings are expected to sustain the growth trajectory. However, the stock trades at a significant premium to sub‑industry and historical multiples, raising concerns about valuation and execution risk amid ACA affordability pressures.
What did this article say?
Oscar Health Inc. (OSCR) stock climbed 14.9% over the past three months, driven by a 46.2% rise in members to 2.96 million during Q2 2026. The company reported a medical loss ratio improvement from 83% to 75%, reflecting tighter pricing and better cost control. Despite a 12% contraction in the broader ACA market, OSCR captured significant share, indicating strong competitive positioning. Management projected a full‑year medical loss ratio of 81‑82%, suggesting continued underwriting discipline. These developments reinforce the bullish case for OSCR, supporting a positive outlook.
What did this article say?
Oscar Health’s recent enrollment gains are tied to the Affordable Care Act’s expanded premium subsidies, which have boosted affordability and attracted new members to its technology‑driven platform. The company plans to enter over 150 additional metropolitan areas by 2027, aiming to broaden its geographic footprint and leverage economies of scale. By disciplining pricing and improving medical‑cost management, Oscar seeks to convert enrollment growth into sustainable profitability, positioning itself as a competitive player in the evolving digital health market.
What did this article say?
Oscar Health, Inc. (OSCR) closed the trading session at $32.91, outperforming the S&P 500 and other major indices. The company’s earnings per share were projected at –$0.11, a 79.25% improvement from the prior year’s quarter, while revenue was expected to reach $4.72 billion, up 58.14% year‑over‑year. Full‑year consensus estimates forecast earnings of $1.83 per share and revenue of $18.81 billion, marking increases of 208.28% and 60.77% respectively. These figures suggest a positive trajectory for OSCR as it prepares for its upcoming earnings release.
What did this article say?
Oscar Health announced Q2 2026 results with earnings from operations of $1.10 billion and net income of $1.00 billion, surpassing expectations. The insurer lifted its full‑year 2026 guidance for both earnings and revenue, citing its AI‑driven platform as a catalyst for improved claims accuracy, cost management, and membership growth. The market reacted strongly, with shares rising 8.6% on the announcement. The upgraded outlook and AI focus represent a significant positive catalyst for the company’s future performance.
What did this article say?
Oscar Health (OSCR) was noted to trade at a price‑to‑book ratio of 4.65, above the industry average, reflecting investor confidence in its technology‑driven model. Analysts highlighted improving medical loss ratios and SG&A efficiencies as drivers of future margin expansion. The company’s full‑stack platform positions it to capture growth in the U.S. individual health insurance market. Comparisons to peers such as Molina and Centene underscored OSCR’s outperformance, with a 142.5% year‑to‑date gain. The commentary concluded that the premium valuation is justified by long‑term growth prospects.
What did this article say?
Oscar Health (NYSE:OSCR) published the full transcript of its second‑quarter 2026 earnings conference call. The call covered the company’s financial performance, operational highlights, and strategic priorities for the remainder of the year. No new guidance or material corporate actions were disclosed during the discussion. The transcript provides context for analysts reviewing the company’s quarterly results but does not alter the current outlook.

Technical Analysis

Real-time indicators across multiple timeframes

86
BULLISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $2.32B combined position · 18 adding, 7 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
BlackRock, Inc.▲ Buy20,587,4286.81%$587.15M2026-08-07
D. E. Shaw & Co., Inc.▲ Buy12,643,6174.19%$360.60M2026-08-14
Vanguard Group Inc▲ Buy20,701,2506.85%$297.48M2026-01-29
Geode Capital Management, LLC▲ Buy5,819,1861.93%$165.99M2026-08-12
FMR LLC (Fidelity)▲ Buy4,998,5231.65%$142.56M2026-08-13
Citadel Advisors LLC▲ Buy4,229,5521.40%$120.63M2026-09-02
Two Sigma Investments, LP▲ Buy4,035,6891.34%$115.10M2026-08-14
Renaissance Technologies LLC▲ Buy3,284,5001.09%$93.67M2026-08-13
Goldman Sachs Group Inc▲ Buy2,289,5570.76%$65.30M2026-08-14
Northern Trust Corp▲ Buy2,211,2090.73%$63.06M2026-08-13
Morgan Stanley▼ Sell2,114,2800.70%$60.30M2026-08-13
Bank of America Corp▼ Sell1,318,1730.44%$37.59M2026-08-14
JPMorgan Chase & Co▼ Sell885,5580.29%$26.39M2026-08-12
Wells Fargo & Company▲ Buy820,7890.27%$23.41M2026-08-14
Point72 Asset Management, L.P.▼ Sell799,7620.26%$22.81M2026-08-14
Balyasny Asset Management L.P.▲ Buy708,6690.23%$20.21M2026-08-14
Millennium Management LLC▲ Buy641,3780.21%$18.29M2026-08-14
Wellington Management Group LLP▲ Buy603,6750.20%$17.22M2026-08-14
Marshall Wace, LLP▼ Sell598,1470.20%$17.06M2026-08-13
AQR Capital Management LLC▲ Buy558,9540.19%$15.94M2026-08-14
Invesco Ltd.▲ Buy472,3820.16%$13.47M2026-08-14
Susquehanna International Group, LLP▼ Sell469,5650.16%$13.39M2026-08-14
Prudential Financial Inc▲ Buy343,3700.11%$9.79M2026-08-12
Squarepoint Ops LLC▼ Sell321,3960.11%$9.17M2026-08-14
Bridgewater Associates, LP▲ New213,7040.07%$6.09M2026-08-14
Q2 2026 flow:23.93M sh bought ($682.39M)8.17M sh sold ($233.41M)net +15.76M sh (+$448.98M)